Clinical trial · Interventional
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA is performed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Promyelocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| all-trans retinoid acid | Drug | — | UNRESOLVED |
| cytarabine | Drug | Cytarabine | ALIAS |
| daunorubicin | Drug | Daunorubicin | ALIAS |
| idarubicin | Drug | Idarubicin | ALIAS |
| mitoxantrone | Drug | Mitoxantrone | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall survival
Secondary outcomes (5)
- measure
- toxicity of the regimen
- measure
- evaluation of additional risk factors
- measure
- effectiveness of MRD as guidance for therapy decisions
- measure
- relapse free survival
- measure
- complete remission rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * acute promyelocytic leukemia confirmed by detection of t(15;17) and/or PML/RARa * no contraindication for chemotherapy * written informed consent Exclusion Criteria: \- severe comorbidities
References
Publications (0)
Data not yet available